Response to comment on ‘Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial’

被引：0
|
作者：
M L Subramanian
机构：
[1] Boston University School of Medicine and the VA Boston Healthcare System,Department of Ophthalmology
来源：
Eye | 2011年 / 25卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：820 / 820
相关论文
共 50 条
  • [21] External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration - One-year results of a prospective, double-masked, randomized clinical trial
    Marcus, DM
    Sheils, WC
    Johnson, MH
    McIntosh, SB
    Leibach, DB
    Maguire, A
    Alexander, J
    Samy, CN
    ARCHIVES OF OPHTHALMOLOGY, 2001, 119 (02) : 171 - 180
  • [22] External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: 4-year results of a prospective, double-masked, randomized clinical trial
    Lott, MN
    Marcus, DM
    Sheils, WC
    Johnson, MH
    Samy, CN
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U692 - U692
  • [23] Randomized Study of Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Inappropriate Conclusions
    Messori, Andrea
    Fadda, Valeria
    Trippoli, Sabrina
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2010, 149 (05) : 867 - 867
  • [24] Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial
    Jackson, Timothy L.
    Desai, Riti
    Wafa, Hatem A.
    Wang, Yanzhong
    Peacock, Janet
    Peto, Tunde
    Chakravarthy, Usha
    Dakin, Helen
    Wordsworth, Sarah
    Lewis, Cornelius
    Clinch, Patricia
    Ramazzotto, Lisa
    Neffendorf, James E.
    Lee, Chan Ning
    O'Sullivan, Joe M.
    Reeves, Barnaby C.
    LANCET, 2024, 404 (10447): : 44 - 54
  • [25] RETICULAR PSEUDODRUSEN ARE NOT A PREDICTIVE FACTOR FOR THE 1-YEAR RESPONSE TO INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Nghiem-Buffet, Sylvia
    Giocanti-Auregan, Audrey
    Jung, Camille
    Dubois, Lise
    Dourmad, Pauline
    Galbadon, Lea
    Fajnkuchen, Franck
    Quentel, Gabriel
    Cohen, Salomon Y.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 (01): : 53 - 59
  • [26] Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial
    Dakin, Helen A.
    Wordsworth, Sarah
    Rogers, Chris A.
    Abangma, Giselle
    Raftery, James
    Harding, Simon P.
    Lotery, Andrew J.
    Downes, Susan M.
    Chakravarthy, Usha
    Reeves, Barnaby C.
    BMJ OPEN, 2014, 4 (07):
  • [27] Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
    Kodjikian, Laurent
    Decullier, Evelyne
    Souied, Eric H.
    Girmens, Jean-Francois
    Durand, Emilie E.
    Chapuis, Francois R.
    Huot, Laure
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 252 (10) : 1529 - 1537
  • [28] Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
    Laurent Kodjikian
    Evelyne Decullier
    Eric H. Souied
    Jean-François Girmens
    Emilie E. Durand
    François R. Chapuis
    Laure Huot
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252 : 1529 - 1537
  • [29] Comparison trial reveals bevacizumab to be as effective as ranibizumab for treating age-related macular degeneration
    不详
    EXPERT REVIEW OF OPHTHALMOLOGY, 2011, 6 (03) : 279 - 279
  • [30] The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
    Unsal, Erkan
    Cubuk, Mehmet Ozgur
    JOURNAL OF CURRENT OPHTHALMOLOGY, 2018, 30 (04): : 337 - 342
12345